Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF

RATIONALE: Idiopathic pulmonary fibrosis (IPF) is the most rapidly progressive and fatal of all fibrotic conditions with no curative therapies. Common pathomechanisms between IPF and cancer are increasingly recognised, including dysfunctional pan-PI3 kinase (PI3K) signalling as a driver of aberrant...

Descripción completa

Detalles Bibliográficos
Autores principales: Mercer, Paul F, Woodcock, Hannah V, Eley, Jessica D, Platé, Manuela, Sulikowski, Michal G, Durrenberger, Pascal F, Franklin, Linda, Nanthakumar, Carmel B, Man, Yim, Genovese, Federica, McAnulty, Robin J, Yang, Shuying, Maher, Toby M, Nicholson, Andrew G, Blanchard, Andy D, Marshall, Richard P, Lukey, Pauline T, Chambers, Rachel C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Interstitial Lung Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975851/
https://www.ncbi.nlm.nih.gov/pubmed/27103349
http://dx.doi.org/10.1136/thoraxjnl-2015-207429

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975851/
https://www.ncbi.nlm.nih.gov/pubmed/27103349
http://dx.doi.org/10.1136/thoraxjnl-2015-207429

Ejemplares similares